Director of the Office of Research Regulatory Affairs at Nationwide Children’s Hospital. As a RAC-certified regulatory professional, he advises the development and regulatory strategy of novel drugs, biologics and devices with extensive focus on cell and gene therapy. 

First sickle cell disease patient, who volunteered in 2019 for the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. Mother of four from Forest, Mississippi, she is a sickle cell warrior having received a CRISPR-based therapy for SCD.

Chair of the Sickle Cell Society (UK). Michele was formerly the Vice-Chair & Treasurer and has been working for the Sickle Cell Society since 2014, contributing to its goal to support and represent people affected by sickle cell, to improve their overall quality of life.

Clinician-scientist in the Department of Bone Marrow Transplantation and Cellular Therapy at St. Jude Children’s Research Hospital. He is an expert in development of novel gene editing therapeutics, and his research includes transplant and gene therapy clinical trials for patients with SCD.